Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|May 1, 2003
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-05-01-2003
- Volume 15
- Issue 5
Qualification of a Chromotographic Column
In this article, five industry experts share their insights to ensure that your column qualification protocols can survive the increased scrutiny of FDA inspectors.
Advertisement
The US Food and Drug Administration (FDA) has become more knowledgeable regarding process chromatography - and more demanding concerning column qualification. In this article, five industry experts share their insights on how to qualify a chromatographic column. Their advice: write unambiguous standard operating procedures (SOPs); focus on the reproducibility of column packing; choose appropriate metrics; and analyse your testing procedures to reduce the chance of erroneous results.
This article is currently available in printed form only.
To ensure access to all articles from every issue of Pharmaceutical Technology Europe
Articles in this issue
over 23 years ago
The New Tabletting Facilityover 23 years ago
Nobler in the Mind? The Dilemma for European Researchover 23 years ago
The Death of the Drug Dossierover 23 years ago
Drug safety in the limelightover 23 years ago
21 CFR Part 11: The New Draft GuidanceAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
2
Can Continuous Tableting End Scale-Up for Complex Oral Drugs?
3
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
4
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
5